Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of liver disease
that poses a global health threat because of its potential to progress to advanced fibrosis …

Damage-associated molecular patterns are signalling molecules involved in inflammatory
responses and restoration of homeostasis. Chronic release of these molecules can also …

Introduction High calorie intake is known to induce nonalcoholic fatty liver disease (NAFLD)
by promoting chronic inflammation. However, the mechanisms are poorly understood …

Single-cell RNA-seq reveals the role of pathogenic cell populations in development and
progression of chronic diseases. In order to expand our knowledge on cellular …

Non‐alcoholic steatohepatitis (NASH) is associated with a disturbed metabolism in liver,
insulin resistance, and excessive accumulation of ectopic fat. Branched‐chain amino acids …

Non-alcoholic steatohepatitis (NASH) signified by hepatic steatosis, inflammation,
hepatocellular injury, and fibrosis is a growing cause of chronic liver disease, cirrhosis, and …

Semaglutide, a glucagon-like peptide-1 receptor agonist, is an antidiabetic medication that
has recently been approved for the treatment of obesity as well. Semaglutide is postulated to …

Concerns have been raised about whether preclinical models sufficiently mimic molecular
disease processes observed in nonalcoholic steatohepatitis (NASH) patients, bringing into …

Non-alcoholic steatohepatitis (NASH) is a fast-growing liver disorder that is associated with
an increased incidence of cardiovascular disease and type 2 diabetes. Animal models …

Obesity characterized by adiposity and ectopic fat accumulation is associated with the
development of non-alcoholic fatty liver disease (NAFLD). Treatments that stimulate lipid …